USPTO serial 79410216
SYGNATURE DISCOVERY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 13, 2026
- Examiner
- MARSH, LAURA KATHLEEN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYGNATURE DISCOVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Molly T. Eichten
Molly T. Eichten Larkin Hoffman Daly & Lindgren Ltd.8300 Norman Center DriveSuite 1000Minneapolis, MN 55437-1060Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Proteins for industrial use; proteins for use in manufacture; proteins for use in scientific research; proteins for use in the manufacture of pharmaceutical products; protein in raw material form for material science, agritech, cosmeceutical research; protein in raw material form for industrial use; protein in raw material form for use in manufacture; protein in raw material form for use in scientific research; protein in raw material form for use in the manufacture of pharmaceutical products. | ACTIVE | — |
| 040 | Processing of organic chemical liquids in the nature of chemical distillery services; recycling of organic solvents; purification of proteins; purification of proteins by chemical methods. | ACTIVE | — |
| 042 | Scientific research and development services; drug discovery services; development of pharmaceutical preparations and medicines; drug screening for scientific research purposes; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of human and veterinary pharmaceutical drugs; research relating to medicines; services for assessing the efficacy of human and veterinary pharmaceutical drugs, namely, human and veterinary pharmaceutical product evaluation, human and veterinary pharmaceutical drug discovery services; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and developments; development of pharmaceutical preparations and medicines; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and drug development; research and development in the pharmaceutical and drug development fields; testing of pharmaceutical drugs; assay development services being custom design and development of biophysical, biochemical, cell-based, phenotypic, in-vitro and in-vivo, assays; biological research; biological analysis; biological research laboratory services; biological research, clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases and medical research; consultancy relating to pharmacology; medical and pharmacological research services; scientific research for medical purposes in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; research in the field of synthetic biology; research and development in the field of microorganisms and cells; chemical research and analysis services; chemical engineering; chemistry services, namely, laboratory research in the field of chemistry; medicinal, synthetic, analytical and high throughput chemistry services, namely, hit generation and optimization, lead optimisation, scale up manufacture, metabolite, analogue, impurity, and analytical standard synthesis and/or isolation and purification, structure elucidation; clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; organic chemistry research and analysis services; consultancy in the field of organic chemistry; laboratory research and analysis services in the field of organic chemistry; research and development services in the field of organic chemistry; development, testing and analysis of chemicals; development, testing and analysis of chemical production methods; protein and peptide mapping for scientific purposes; scientific analysis services, namely, scientific analysis of materials for human and veterinary pharmaceutical, material science, agritech, cosmeceutical research for scientific research purposes; protein analysis services for scientific purposes; scientific research in the field of protein sequencing; protein crystallisation screening for scientific purposes; quality control for others; testing of materials; product testing; technological research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; industrial analysis and research services in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; scientific services relating to cell line generation; scientific screening services being ion channel screening, iterative screening, fragment screening and in silico screening, for scientific research purposes; compound profiling and selectivity services; X-ray and cryoelectronmicroscopy imaging and NMR structure determination of proteins, biological macromolecules and molecules, other than for medical purposes; blood analysis services for scientific research purposes; information, advisory and consultancy services relating to the aforesaid services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sygnature Discovery Limited
- Other trademarks owned by Sygnature Discovery Limited
- Other trademarks owned by Sygnature Discovery Limited
- Other trademarks in Class 001
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named SYGNATURE DISCOVERY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 6, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 18, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 18, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 7, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 20, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 20, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 13, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 27, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 24, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 24, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 9, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 24, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 24, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 14, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 25, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 25, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |